A nurse is caring for a client who has substance use disorder who has expressed interest in receiving treatment to stop using. Which of the following Interventions is an example of a tertiary intervention strategy for this client?

D. A relapse plan is an essential component of managing schizophrenia and other mental health conditions. It helps individuals recognize early warning signs of a potential relapse and outlines steps to take to prevent or mitigate the worsening of symptoms. By having a relapse plan in place, the client can actively participate in their own recovery process and take proactive steps to maintain stability and well-being.

A. This response focuses on practical aspects such as living arrangements and employment, which may be components of a comprehensive care plan but may not fully address the client's question about the need for a relapse plan.

B. This response acknowledges the purpose of a relapse plan in helping the client manage their symptoms and cope with challenges while living in the community. However, it may not fully address the client's question about the need for a relapse plan.

C. While hospitalization may be a component of a relapse plan in certain circumstances, focusing solely on this aspect may not fully address the client's question and may inadvertently increase anxiety or stigma associated with hospitalization.

C. Psychiatric pharmacogenomic testing involves analyzing an individual's genetic makeup to predict their response to psychiatric medications. This testing provides healthcare providers with information about how an individual's genetic variations may impact their metabolism of medications.

A. Psychiatric pharmacogenomic testing can inform treatment decisions but it does not determine the likelihood of a cure. Mental illness is complex and often requires multimodal treatment approaches beyond medication alone.

B. Pharmacogenomic testing can provide information about how an individual's genetics may interact with specific medications but it primarily focuses on identifying which medications are likely to be most effective for the individual, rather than interactions between medications.

D. Psychiatric pharmacogenomic testing does not determine the cause of mental illness. Mental illnesses are multifactorial and have complex etiologies involving genetic, biological, environmental, and psychosocial factors.